Pharmaceutical Grade Sodium Chloride Market Analysis, By Grade / Use (Parenteral/infusion grade (IV solutions), Hemodialysis grade, Oral/enteral & irrigation grade, General pharma processing grade, and Others), By Form (Crystalline/powder, Granules, Solution/brine/concentrates and Others), By End User (IV/parenteral manufacturers, Dialysis solution manufacturers, Oral/enteral manufacturers, CMOs, and Others), and Regional Forecast 2026-2034

The pharmaceutical grade sodium chloride market size was valued at USD 1.10 billion in 2025. The market is projected to grow from USD 1.16 billion in 2026 to USD 1.80 billion by 2034, exhibiting a CAGR of 5.6% during the forecast period.

The pharmaceutical grade sodium chloride market is poised for significant growth. The market growth is attributed to the rising use of injectable and IV products in hospital settings and the expansion of manufacturing capabilities across the globe. To cater to the increasing demand, key companies are engaging in strategic collaborations and acquisitions, thereby reinforcing market growth.

• For instance, in December 2025, ContextLogic Holdings Inc. acquired US Salt Parent Holdings, LLC, a producer of high-purity pharmaceutical-grade evaporated salt products.

Furthermore, the launch of new facilities, expansion of production facilities, and strategic partnerships and collaborations by key companies are expected to solidify their market dominance.

Pharmaceutical Grade Sodium Chloride Market Driver

Rising Prevalence of Chronic Kidney Diseases to Drive Market Growth

The rising prevalence of chronic kidney disease is a significant factor driving the growth of the pharmaceutical grade sodium chloride market. As chronic kidney disease progresses, the number of patients who require hemodialysis and related renal replacement therapies increases. These therapies require high-purity salts to manufacture dialysate concentrates and solutions. As CKD patient volumes rise, dialysis providers and solution manufacturers scale procurement of compliant sodium chloride to ensure a consistent supply. These factors drive the market growth.  

• For instance, in July 2019, according to the Centers for Disease Control and Prevention (CDC), the number of American adults with chronic kidney disease (CKD) was estimated to be around 37.0 million.

Download Free sample to learn more about this report.

According to the International Society of Nephrology, the prevalence of CKD worldwide is 10.4% among men and 11.8% among women.

Pharmaceutical Grade Sodium Chloride Market Restraint

Recalls and Other Adverse Quality Events to Hamper Market Growth

Recalls and other adverse quality events restrain the pharmaceutical grade sodium chloride market. Such events affect the distribution, forcing IV and dialysis manufacturers to revalidate alternate sources. As a result, buyers increase safety stocks and add extra audits, which raises procurement costs and slows purchasing decisions. At the same time, suppliers face disruption-related costs and reputational risks, which limit market growth.

• For instance, in August 2025, Braun Medical recalled 0.9% Sodium Chloride Injection USP, 1000 mL, due to the presence of particulate matter inside the container. Such adverse events disrupt supply availability and trigger requalification/switching actions for hospitals and manufacturers, thereby restraining market growth opportunities.

Pharmaceutical Grade Sodium Chloride Market Opportunity

Expansion of Manufacturing Capacity to Offer Lucrative Market Growth Opportunity

Expanding pharma-grade sodium chloride manufacturing capacity offers significant growth opportunities for the market, as demand from dialysis solutions and IV/infusion fluids continues to rise. These products need high-purity salt that meets pharmacopoeial/GMP standards, prompting buyers to prefer suppliers that can provide consistent quality and reliable volumes. When suppliers add dedicated pharma-grade production lines and increase output, they can reduce shortages, meet long-term demand, and support customers as they scale dialysis and infusion manufacturing. Such factors encourage strategic partnerships among companies and provide opportunities for market growth.

• For instance, in May 2023, Wincanton partnered with Tata Chemicals Europe and signed a 10-year warehousing and logistics contract. The collaboration supported the strategic growth plans for the high-purity salt manufacturing business.

Segmentation

Key Insights

The report covers the following key insights:

• Key Industry Developments
• Overview: Advancements in Pharmaceutical Grade Sodium Chloride
• New Product Launches, By Key Players
• Analysis: Emerging Application Areas for Pharmaceutical Grade Sodium Chloride

Analysis by Grade/Use

In terms of grade/use, the global pharmaceutical grade sodium chloride market is segmented into parenteral/infusion grade, hemodialysis grade, oral/enteral & irrigation grade, general pharmaceutical processing grade, and others.  

Parenteral/infusion grade products are anticipated to hold a leading market share. This grade typically accounts for the largest share because IV fluids and injectable formulations consume the most sodium chloride. Hospitals use saline widely for hydration, electrolyte replacement, and flushing, among other purposes, which creates a steady baseline demand across acute care, surgery, and emergency settings. Many key companies are directing their resources towards new product launches in the segment, underscoring its growth potential.

• For instance, in May 2024, B. Braun Medical Inc., a leader in smart infusion therapy and pain management, launched its new Levetiracetam in Sodium Chloride Injection line of products. This new product expanded the company's portfolio in the anticonvulsant space.

Analysis by Form

Based on form, the global pharmaceutical grade sodium chloride market is segmented into crystalline/powder, granules, solution/brine/concentrates and others.

The crystalline/powder segment dominated the global market. Crystalline or powdered sodium chloride is the most commonly used, as it is stable, easy to store and transport, and flexible for manufacturers to dissolve on-site to their required concentration. This form also allows better control over batching, filtration, and sterilization steps in downstream processing. These advantages result in a higher preference for this form, encouraging them to expand their product offering.

• For instance, in March 2022, Spectrum Chemical Mfg. Corp added 12 new products to its rapidly growing bioCERTIFIED quality management system and chemicals portfolio for biopharmaceutical manufacturing. These factors are expected to drive the segmental growth.

Analysis by End User

In terms of end-user, the market is segmented into IV/parenteral manufacturers, dialysis solution manufacturers, oral/enteral manufacturers, CMOs, and others.

IV/parenteral manufacturers are expected to hold a leading share of the global market. IV and parenteral product manufacturers serve the highest throughput and meet stringent quality and compliance requirements. Their production runs are continuous, with a reliable supply chain. These factors result in substantial quantities of pharmaceutical-grade NaCl. Their broad and frequent use of IV saline and injectable dilution, as well as for hypertensives across healthcare, reinforces their market dominance.

• For instance, in November 2024, Baxter International Inc. expanded its Pharmaceuticals portfolio with five injectable product launches in the U.S. that focused on differentiated products addressing unmet patient needs, including anti-infective and anti-hypotensive medications. Such developments are expected to drive the segmental growth.

Regional Analysis

Request for Customization   to gain extensive market insights.

By region, the market is categorized into Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for approximately 35% of the global pharmaceutical grade sodium chloride market in 2025. The market growth in the region is attributed to the increasing use of sodium chloride in sterile injectables, used mainly in IV therapy, across various healthcare providing centers. Manufacturers keep tight quality specifications for injectable-grade inputs, which supports steady demand for pharmaceutical grade sodium chloride. Additionally, the higher chronic disease burden in the region of kidney-related disorders reinforces the dialysis-related consumption, as critical IV fluid ingredients are anticipated to drive demand. Underscoring this growing demand, key companies are also expanding their product offering for the segment to capitalize on market growth.

• For instance, in September 2025, Endo, a subsidiary of Mallinckrodt plc, launched ADRENALIN (epinephrine in 0.9% sodium chloride injection) in a premixed IV form. With this launch, Endo expands its ADRENALIN portfolio to include premixed IV bags in five concentrations: 2 mg, 4 mg, 5 mg, 8 mg, and 10 mg per 250 mL. The portfolio also included ADRENALIN (epinephrine injection, USP) in 1 mL single-dose and 30 mL multi-dose vials. Such developments drive the market growth in the region.

Europe is expected to grow at a significant CAGR during the forecast period due to the growing geriatric population and strong demand for hospital-based treatments where saline is routinely used. The region has a large production capacity for generic and sterile injectables, which drives demand for pharmaceutical grade sodium chloride. Increasing utilization in chronic kidney disease management also drives demand for high-purity salt for dialysis. To cater to the growing demand, many key companies in the region are focusing on capacity expansion and further supporting the market's growth.

• For instance, in 2021, the CIECH Group, one of the leading salt producers in Europe, launched a new production facility in Stassfurt. With this new production facility, the company was able to produce approximately 450,000 tons of evaporated salt annually. Such developments drive the growth in the region.

Asia Pacific is expected to grow at the fastest CAGR during the forecast period because healthcare spending in the region is increasing. With the expansion of healthcare access, treatment volumes are increasing, driving market growth. The region is also witnessing a rising prevalence of diabetes and hypertension, which drives more chronic kidney disease and dialysis demand over time.  Such a factor increases the demand for pharmacopoeial-grade sodium chloride, driving market growth. These emerging nations are also highly focused on the production of several generics, which increases the consumption of pharmaceutical grade sodium chloride for manufacturing.

• For instance, in January 2023, Genovior Biotech expanded its sterile injectable manufacturing capacity, enabling large-scale commercial production of peptide medicines and specialty sterile dosage forms for global markets. IV fluids include normal saline, which is made from pharmaceutical grade sodium chloride—such developments are expected to boost market demand.

Key Players covered

The global pharmaceutical grade sodium chloride market is semi-consolidated, with a few players capturing a significant market share.

The report includes the profiles of the following key players.

• K+S Aktiengesellschaft (Germany)
• Salins Group (France)
• Cargill, Incorporated. (U.S.)
• Compass Minerals. (U.S.)
• Tata Chemicals. (India)
• INEOS AG. (U.S.)
• Dominion Salt (New Zealand)
• Salinen Austria Aktiengesellschaft (Austria)
• Morton Salt, Inc. (U.S.)

Key Industry Developments

• March 2025: c-LEcta launched the GMP-grade version of DENARASE High Salt, a strategic extension of its DENARASE portfolio. The development is intended to serve customers with clinical and commercial stage processes that require compliance with the highest quality standards.
• December 2024: Brenntag partnered with K+S Minerals and Agriculture GmbH for the worldwide distribution of three pharmaceutical salts: APISAL Sodium Chloride GMP, Potassium Chloride 99.9% KCl Ph. Eur., USP (API), and HD-NaCl. The development strengthened the role as a key supplier to the global healthcare industry.